
Health
National Cancer Institute Launches Ivermectin Cancer Study Under RFK Jr.'s NIH, Alarming Scientists
The National Cancer Institute, the premier cancer research body in the United States, is now using federal funds to investigate whether ivermectin — the cheap anti-parasitic drug that became a symbol
Key Takeaways
- The National Cancer Institute launches a preclinical ivermectin cancer study under Trump-appointed NCI Director Anthony Letai
- Scientists are alarmed because no credible evidence supports ivermectin as an oncological treatment in humans
- The study was announced at a MAHA Institute event featuring NIH Director Jay Bhattacharya, raising politicization concerns
DE
DT Editorial AI··via arstechnica.com